Sage Therapeutics to seek approval of postpartum depression drug after trial win

Cambridge biotech Sage Therapeutics says it plans to apply for U.S. approval of its experimental drug to treat postpartum depression next year after the drug achieved the main goals in two late-stage trials involving more than 200 women. The company's stock soared 67 percent in premarket trading Thursday morning to more than $100 a share. If the stock spike holds when market opens it would add nearly $1.4 billion to its market capitalization. Sage (Nasdaq: SAGE), which had 135 employees as of February,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news